Search results for "AGENTS"

showing 10 items of 7330 documents

Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up.

1998

Acute infection with hepatitis C virus (HCV) develops into a chronic hepatitis in about 50-70% of patients. Treatment of these patients with interferon-alpha (IFN-alpha) results in a sustained long-term response in only 15-20% but causes numerous unwanted side-effects in a higher percentage of patients. The aim of our study was to define host or viral parameters that would allow identification of responders and non-responders to IFN-alpha prior to the onset of treatment. We studied a group of 87 patients suffering from chronic hepatitis C who were treated with IFN-alpha. After long-term follow-up, 18 patients (21%) showed a sustained response to IFN-alpha therapy (normalization of serum tra…

AdultMaleNecrosisGenotypeHepatitis C virusAlpha interferonInflammationHepacivirusmedicine.disease_causeAntiviral AgentsFibrosisVirologyGenotypemedicineHumansViremiaHepatologymedicine.diagnostic_testbusiness.industryTumor Necrosis Factor-alphaInterferon-alphaHLA-DR AntigensHepatitis C ChronicMiddle AgedViral Loadmedicine.diseaseInfectious DiseasesTreatment OutcomeLiver biopsyImmunologyRNA ViralFemalemedicine.symptombusinessViral hepatitisFollow-Up StudiesJournal of viral hepatitis
researchProduct

Desmopressin in the Treatment of Nocturia: A Double-Blind, Placebo-Controlled Study

2007

Objectives: To investigate efficacy, safety, and impact on quality of sleep of desmopressin in the treatment of nocturia. Methods: Adults aged >= 18 yr with nocturia (>= 2 voids/night) received desmopressin tablets (0.1, 0.2, or 0.4 mg) during a 3-wk dose-titration period. Patients should show sufficient response during the dose-titration period (>= 20% reduction in nocturnal diuresis) and a return of nocturnal diuresis to >= 80% of baseline levels during washout. Eligible patients then entered a 3-wk double-blind treatment period and received either desmopressin or placebo. Results: 127 patients were randomised to either desmopressin (n = 61) or placebo (n = 66). Twenty (33%) desmopressin-…

AdultMaleNephrologymedicine.medical_specialtyUrologyPlacebo-controlled studyAdministration OralDiuresisPlaceboDouble-Blind MethodInternal medicinemedicineHumansNocturiaDeamino Arginine VasopressinDesmopressinAdverse effectAgedAged 80 and overDose-Response Relationship Drugbusiness.industryAntidiuretic AgentsMiddle AgedSurgeryUrodynamicsTreatment OutcomeAnesthesiaFemaleNocturiamedicine.symptomSleepbusinesshormones hormone substitutes and hormone antagonistsFollow-Up Studiesmedicine.drugAntidiureticEuropean Urology
researchProduct

Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma

2013

Background: Neutropenia and its complications represent one of the principal dose-limiting toxicity issues in chemotherapeutic regimens for soft tissue sarcoma. Prophylactic granulocyte colony-stimulating factor (G-CSF) reduces the risk of febrile neutropenia (FN). The correct timing of G-CSF administration should be considered in order to optimize the prophylactic treatment. Patients and Methods: Patients (≥18 years old) affected by soft tissue sarcoma and treated with epirubicin and ifosfamide, underwent prophylactic treatment with G-CSF (lenograstim at 263 μg) from day 5 to day 9. The proportion of patients experiencing FN and G4 neutropenia was considered. Results: A total of 36 patient…

AdultMaleNeutropeniaSettore MED/06 - Oncologia MedicaAntineoplastic AgentsSarcomaSoft Tissue Neoplasmslenograstrim sarcoma neutropeniaMiddle AgedLenograstim Febrile Neutropenia Soft tissue sarcomaLenograstimRecombinant ProteinsYoung AdultAdjuvants ImmunologicGranulocyte Colony-Stimulating FactorHumansFemaleIfosfamideAgedEpirubicin
researchProduct

Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib

2017

<b><i>Background/Aim:</i></b> Individual components of the metabolic syndrome (MS) such as obesity or diabetes mellitus impair the prognosis of patients with hepatocellular carcinoma (HCC) following curative treatment approaches or transarterial therapies. The aim of this retrospective study was to assess the impact of these factors on the overall survival (OS) of patients with advanced HCC treated with sorafenib. <b><i>Methods:</i></b> Univariate and multivariate analyses were performed to assess the impact of individual components of the MS on the OS of 152 consecutive patients with advanced HCC treated with sorafenib. <b><i>Resu…

AdultMaleNiacinamideOncologySorafenibmedicine.medical_specialtyCarcinoma HepatocellularAntineoplastic AgentsYoung Adult03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicinemedicineHumansSurvival analysisAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesAged 80 and overMetabolic Syndromebusiness.industryProportional hazards modelPhenylurea CompoundsLiver NeoplasmsHazard ratioGastroenterologyGeneral MedicineMiddle AgedSorafenibPrognosismedicine.diseaseSurvival Analysisdigestive system diseasesTreatment OutcomeDiabetes Mellitus Type 2030220 oncology & carcinogenesisHepatocellular carcinomaMultivariate AnalysisFemale030211 gastroenterology & hepatologyMetabolic syndromebusinessDyslipidemiamedicine.drugDigestive Diseases
researchProduct

Relaxation and cyclic GMP levels in response to sildenafil in human pulmonary arteries from donors.

2005

We measured cyclic GMP formation and relaxation response to sildenafil given either alone or in combination with sodium nitroprusside (SNP) in pulmonary arteries obtained from 13 multi-organ donors. Sildenafil (10(-9)-10(-4) M) caused concentration-dependent relaxations and amplified the relaxation induced by SNP. Relaxation was unaffected by endothelium removal or by pre-treatment with the inhibitor of nitric oxide synthase L-NMMA (10(-4) M). SNP (10(-7) M) caused elevation of cyclic GMP levels that was potentiated by sildenafil (10(-6) M). Thus, the enhancement of SNP-induced relaxation by sildenafil is mainly due to an increase in cyclic GMP accumulation.

AdultMaleNitroprussideEndotheliumSildenafilPhosphodiesterase InhibitorsVasodilator AgentsVasodilationPharmacologyIn Vitro TechniquesPulmonary ArteryPiperazinesSildenafil CitrateNitric oxidechemistry.chemical_compound3'5'-Cyclic-GMP PhosphodiesterasesmedicineHumansNitric Oxide DonorsSulfonesCyclic GMPPharmacologybiologyChemistryDrug SynergismMiddle Agedrespiratory tract diseasesNitric oxide synthaseVasodilationmedicine.anatomical_structureBiochemistryEnzyme inhibitorPurinesCirculatory systemcardiovascular systembiology.proteinFemaleSodium nitroprussidemedicine.drugEuropean journal of pharmacology
researchProduct

Bipolar II disorders in six first-degree relatives

1993

As proposed by Dunner et al (1976), the distinction of bipolar !! disorder from other effective disorders has been included in Research Diagnostic Criteria (RDC) (Spitzer et al 1978) but not in DSM-IiI-R or ICD 10 (APA 1987, WHO 1991). Family studies indicate that bipolar 1I disorder might represent a distinct diagnostic entity with a common genetic background (Gershon et al 1982; Dunner 1983; Endicott et al 1985; Andreasen et al 1987). Familial aggregation, diagnostic stability, and course of illness represent external validators for nosologic classifications (Kendler 1990). Therefore, pedigrees with multiple cases of diagnostically stable bipolar Ii disorder without cases of bipolar 1 dis…

AdultMaleNosologymedicine.medical_specialtyBipolar DisorderResearch Diagnostic CriteriaPedigree chartAntidepressive Agents TricyclicBipolar II disordermental disordersmedicineHumansFamilyBipolar disorderFirst-degree relativesPsychiatryBiological PsychiatryAgedPsychiatric Status Rating ScalesFamily aggregationICD-10Middle Agedmedicine.diseasePedigreeFemalePsychologyBiological Psychiatry
researchProduct

High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia.

2003

The 'atypicality' of the antipsychotic drug, amisulpride, has been attributed to preferential extrastriatal binding. Previous investigations of striatal D2 receptor occupancy by amisulpride revealed conflicting results. The aim of this PET study was to measure the striatal occupancy by amisulpride and to correlate it with the corresponding drug plasma concentrations. Nine amisulpride-treated patients and 12 healthy volunteers serving as controls were studied with PET and [18F]desmethoxyfallypride. Occupancy values and plasma concentrations were nonlinearly fitted to an E max model. Results showed 43-85% (putamen) and 67-90% (caudate) D2-like receptor occupancy. Plasma amisulpride concentrat…

AdultMaleOccupancyPharmacologyDopamine receptor D2Image Interpretation Computer-AssistedSalicylamidesmedicineHumansPharmacology (medical)AmisulprideReceptorPharmacologyCerebral CortexChemistryReceptors Dopamine D2PutamenDesmethoxyfallypridePutamenMiddle Agedmedicine.diseaseNeostriatumPsychiatry and Mental healthSchizophreniaDopamine receptorArea Under CurvePositron-Emission TomographySchizophreniaFemaleAmisulprideCaudate NucleusRadiopharmaceuticalsSulpirideAlgorithmsmedicine.drugAntipsychotic AgentsThe international journal of neuropsychopharmacology
researchProduct

Topical Antibiotic, Antifungal, and Antiseptic Solutions Decrease Ciliary Activity in Nasal Respiratory Cells

2002

This study was designed to investigate whether topical solutions, as they are used in the treatment of selected cases of rhinosinusitis, influence nasal mucociliary clearance. The objective of this study was to evaluate the effects of the following topical solutions on the ciliary beat frequency (CBF) of nasal respiratory cells: ofloxacin as an antibiotic; Betadine and hydrogen peroxide (H2O2) as antiseptic; and amphotericin B, itraconazole, and clotrimazole as antifungal solutions. Differences are described between effects of each of these substances and we clarify whether ciliotoxic effects are dose dependent and if they can be reduced or eliminated by diluting the concentration of the a…

AdultMaleOfloxacinAntifungal AgentsMucociliary clearanceItraconazolemedicine.drug_classAntibioticsPharmacologySensitivity and SpecificityMicrobiology03 medical and health sciences0302 clinical medicineAntisepticReference ValuesAmphotericin BAmphotericin BmedicineHumansClotrimazoleRespiratory system030223 otorhinolaryngologyPovidone-IodineCells CulturedDose-Response Relationship Drugbusiness.industryClotrimazoleNasal MucosaOtorhinolaryngologyMucociliary Clearance030220 oncology & carcinogenesisAnti-Infective Agents LocalFemaleOfloxacinItraconazolebusinessmedicine.drugAmerican Journal of Rhinology
researchProduct

Once-Daily Oral Levofloxacin Monotherapy versus Piperacillin/Tazobactam Three Times a Day: A Randomized Controlled Multicenter Trial in Patients with…

2004

A prospective, randomized, controlled multicenter trial was performed to evaluate the efficacy and safety of once-daily oral monotherapy with 500 mg levofloxacin in comparison with 4.5 g piperacillin/tazobactam 3 times a day in patients with low-risk febrile neutropenia. Low risk was defined by oral temperatureor = 38.5 degrees C on one occasion oror = 38.0 degrees C twice within 24 hours and granulocytopeniaor = 500/microL for less than 10 days. The primary end point was defined as defervescence after 72 hours followed by at least 7 afebrile days. Secondary end points were overall response, time to defervescence, survival on day 30, and toxicity. Thirty-four episodes were included. Fever o…

AdultMaleOfloxacinTazobactammedicine.medical_specialtyNeutropeniaFeverAdministration OralPenicillanic AcidAntineoplastic AgentsLevofloxacinNeutropeniaFever of Unknown OriginTazobactamDrug Administration ScheduleImmunocompromised HostLevofloxacinNeoplasmsInternal medicineMulticenter trialHumansMedicineProspective StudiesAgedAntibacterial agentPiperacillinbusiness.industryBacterial InfectionsHematologyMiddle Agedmedicine.diseaseSurgeryTreatment OutcomePiperacillin/tazobactamDrug Therapy CombinationFemaleDisease SusceptibilitySafetybusinessFebrile neutropeniaPiperacillinmedicine.drugInternational Journal of Hematology
researchProduct

Subchronic Effects of Olanzapine on Sleep EEG in Schizophrenic Patients with Predominantly Negative Symptoms

2004

Background It is well known that sleep disturbance is an integral symptom of schizophrenia. In recent studies, a deficit of delta sleep has been observed in schizophrenic patients. Antipsychotic drugs with serotonin (5-HT2) receptor-antagonistic properties are considered to have delta sleep promoting effects. We have investigated the effects of subchronic olanzapine treatment on sleep EEG in schizophrenic patients. Methods The effects of administration of olanzapine (15 to 20 mg) on sleep were studied for four weeks in 10 male, drug-free patients suffering from schizophrenia with predominantly negative symptoms. Conventional sleep EEG parameters were investigated at baseline and after treat…

AdultMaleOlanzapineAdolescentPolysomnographymedicine.medical_treatmentPolysomnographySeverity of Illness IndexDrug Administration ScheduleBenzodiazepinesSurveys and QuestionnairesmedicineHumansPharmacology (medical)AntipsychoticSleep disorderSleep Stagesmedicine.diagnostic_testElectroencephalographyGeneral MedicineMiddle Agedmedicine.diseaseSleep in non-human animalsDiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthDelta RhythmOlanzapineSchizophreniaAnesthesiaDelta RhythmSchizophreniaSchizophrenic PsychologySleep StagesPsychologyAntipsychotic Agentsmedicine.drugPharmacopsychiatry
researchProduct